

Remarks

No new matter has been added. The specification has been amended to direct the entry of this sequence listing after the claims of the above identified application and to provide the SEQ ID NO's next to the specific sequence. Claim 3 has been amended in order to provide a sequence identifier next to the specific peptide.

In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter.


In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

Summary

It is respectfully believed that this application is now in condition for examination.
Early notice to this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Eric K. Steffe
Attorney for Applicants
Registration No. 36,688

Date: February 6, 2002

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

Version with markings to show changes made

In the Specification:

Paragraph beginning at page 1, line 5:

The renin-angiotensin system (RAS) is the name given to the system of substrates and enzymes that gives rise to the active circulating hormone, angiotensin-II. Renin is a proteolytic enzyme secreted into the bloodstream by the juxtaglomerula cells of the kidney. It cleaves a substrate, angiotensinogen, which is a component of the α_2 -globulin fraction of the plasma proteins to yield a decapeptide called angiotensin-I. Two amino acids from the carboxyl terminus of this peptide are, in turn, cleaved by angiotensin converting enzyme (ACE) to produce the active octapeptide angiotensin II:

Asp-Arg-Val-Tyr-Ile-His-Pro-Phe (SEQ ID NO:1).

In the Claims:

3. (Twice amended) A method as claimed in claim 1 wherein the angiotensin is angiotensin-II (SEQ ID NO:1).